Additio Investment Group

Orthox Ltd. is a medical implant company based in Abingdon, United Kingdom, specializing in tissue regenerative implants for patients with knee injuries. Founded in 2008 by Dr. Nick Skaer and Professor Oliver Kessler, the company leverages silk technology developed at Oxford University to create innovative solutions for cartilage and meniscus repair. Its primary products include FibroFix, a biomaterial designed to replicate human knee cartilage; FibroFix Meniscus, which focuses on repairing and regenerating meniscal cartilage; and FibroFix Cartilage, aimed at treating articular cartilage damage. The technology behind these products was originally developed at Oxford Biomaterials Ltd., where Dr. Skaer played a significant role in advancing the FibroFix technology platform before securing exclusive licenses for its application in cartilage and bone repair.

Oxford Endovascular are developing a novel treatment for treating brain aneurysms. The Oxford technology uses a special laser-cut metal alloy which has a shape-memory. It can be posted into a catheter during surgery, inserted into the brain and opened up into a tiny tube mesh (‘flow diverter’) that fits into the natural shape of the blood vessel. This diverts the blood away from the aneurysm, allowing it to heal.

Gedea Biotech AB, founded in 2015 and based in Lund, Sweden, focuses on developing antibiotic-free treatments for vaginal fungal infections, a common issue affecting approximately 75% of women at some point in their lives. The company's primary product, GA101, is a natural substance that functions by lowering the pH in the vaginal environment, providing physical barrier protection, and inhibiting biofilm formation. This innovative approach aims to offer a safe and effective topical treatment for vaginal yeast infections, addressing a significant healthcare need without the use of antibiotics.